IMUX - Earnings call transcript Q2 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Jessica Breu

Good morning, and welcome to Immunic's Second Quarter 2020 Earnings Call. My name is Jessica Breu, Vice President, Investor Relations and Communications at Immunic. I will also be the moderator today.

Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer; Glenn Whaley, our Chief Financial Officer; as well as Jason Tardio, our newly appointed Chief Operating Officer and President.

participants being in recorded. all this mode that is event note will listen-only be and Please After opportunity to presentation, ask today's there questions. will be an

are questions. join ways you the via platform, If webcast to there submit Zoom X

Q&A You can questions directly, to Zoom to your the either please like your use if would with hand cure tool function Zoom via you in in or speak of writing submit the us the question. raise portal

may remind here. we as statements, uncertainties contain involve to I and estimate that risks presentation materially like similar that Before statements those identified may, such And number with meaning. results anticipate, forward-looking differ from to statements words you could be begin, expect, can or cause such words of actual discussed a such this would by will, Immunic's

any Please or forward-looking these light risk of obligation Immunic's the date SEC statements. of opinion forward-looking statements a these to reflect undertakes release presentation, Please affect results Immunic's of publicly to for the description to and the in no of events. future in Immunic's detailed note that it forward-looking more of these and that revision this filings revise only as refer may factors or statements information new result

would Vitt, our turn to I now the Daniel to to CEO, begin Daniel? Dr. like call over the presentation.

Daniel Vitt

the financial XX, for everybody earnings June call. today's results to quarter Earlier months to Jessica. we you, welcome Thank morning, announced would also our like I and XXXX. this ended second X

clinical upcoming results and as will development our our achievements quarter and through second operating walk highlights, During today, as anticipated subsequent milestones. including programs, we the call XXXX well financial

will the presentation, have ask opportunity As questions. the Jessica noted, to you after

San the In as of landscape XXXX neuroprotective highlighting our data well Francisco, and available with MS as worsening disability currently sclerosis potential with April, which the our in second We associated supporting did start MS so highlights. high and development quarter Let's calcium, encouraging compared developments with generated through hosted far our vidofludimus distinction the latest the preclinical we in vidofludimus multiple subsequent a reduce therapies. walked clinical calcium. unique and review program represent

shared also by and comprehensive selectively of the solution neuroprotective, that MS to standard patients [indiscernible] a elevate components that today's tolerability full our profile. antiviral In effects. vidofludimus with We strong it safety care is calcium providing it's spectrum potentially X its for of address could of belief favorable with anti-inflammatory and given combination all designed

able join and want event from our recording. to I extend to to that announced the those listen EMPhASIS who trial us in was patients RMS of journal both Neuroinflammation April, American in for II thanks person journal Phase Also data Academy who is our and extended Neurology, in the everyone again peer-reviewed official vidofludimus Neuroimmunology sclerosis relapsing and prestigious the we remitting in the to of Neurology. published calcium with of multiple

Inclusion also publication data by leads paper RMS programs clinical evidence from represents calcium The study programs cohorts range. extended an for Bob is insurer off with our both CALLIPER from and Cleveland coordinating who the investigator Clinic, included dose Fox various of further May, vidofludimus the mass. conferences. at for findings strength in scientific the data our the in had of these present to we opportunity In of Dr.

histology, and of nutrient improvements in was disease demonstrated molecule our Sirtuin trial and gluten gluten-free Disease Phase disease available X disease results orally patients First IMU-XXX, celiac gathered absorption. with meaningful X presented key challenge diet modulator biomarkers of Week in over Washington in celiac periods in oral in specifically an at during Digestive placebo DC. dimensions clinical The symptoms of pathophysiology, Target our systemically human data that from trial small and presentation Ib acting

in tolerated also was safe and well IMU-XXX observed trial. this

of potential through proof We for gastrointestinal new approach continue architecture. regeneration a therapy, the to the or disorders bowel a concept believe to of of data initial that provides range this

XXth Centers placebo highlight calcium Phase II for The PMS National. sclerosis pleased data XXrd consortium Sands clear of of light this had to patient Neurology in in and or National from Congress vidofludimus calcium conferences. in Meeting observed separation Annual multiple both represented the we at caliber chain meetings We in Additionally, NFL in opportunity have neurofilament to trial were our Golden population. progressive PMS X patients of Bulgaria vidofludimus at a with serum multiple sclerosis over

pharmaceutical As significant be will also strengthened he proven with Chief likely major the Jason of in efforts This as team could to in signal commercialization a our NFL step in caliber of relevant MS. Officer disability ] clinically addition makes more President for calcium. July, trial Jason's first-in-class experience as potential endpoints for like no prepare newly of companies management invaluable be and and in us will lead what and believe role vidofludimus worsening. outcome the prevention Tardio, another it overall as potentially the we forward Operating commercializing MS strong for a well activator of the created biotechnology represents internal In [ for X drugs of launching positive

for can work range partnership experience. outcomes assets extensive will pipeline leverage also our Walsh, Jason we his Officer, where partnering Business our to Patrick of with prepare company for Chief a closely the potential

a XXXX to regarding overall responsibility will and member I he promoted strategic as Board a clinical of in Directors, would Skerjanec Immunic Board for appointment to has recent over words moment take to was In Simona take and of Immunic's new operational of to introduce Jason. Jason Chief like of functions. the have then. Development since Gladdines say January role, and responsibilities operational Officer. additional a positions Werner himself held his few Werner increasing Additionally,

Unknown Executive

excited of individuals living I drugs course Immunic preparation And the my Immunic to both to begin in with my because of during vidofludimus prospect address I vidofludimus calcium talented to I and time key believe in strongly experiences of so much, attracted Immunic the to groundbreaking that sclerosis number to applying X than bringing Thank at as unmet be potential launching morning the more calcium the a vidofludimus for to months. catalysts important progressive truly of the calcium the multiple X to over needs for treatment as here we the then was readouts next pivotal the have you during worldwide. option much-needed still and support such plans. oral potential growth Daniel. a with look to X of numerous has prepare million patients of joined forms career we for and MS. exist a very company's relapsing I'm sclerosis team multiple forward this delighted of this number and

the not to I a for calcium the living global meaningfully XXXX. to This that for [ to tolerability that in market, is of additional distinct a effects sales potential and profile, neuroprotective unique the relapsing to a forecasted encouraging. antiviral grow accounts billion safety options first-in-class share The with dual global progressive today a a and individuals action data And anti-inflammatory effects medicine enhance with only DHODH. selectively date ]activator vidofludimus in MS is by with believe MS year large in combined as market neuron therapeutic both has that is $XX but capture inhibiting both by enzyme billion $XX with to mechanism significant and the and MS, combines favorable

celiac and on prepare available closely IMU-XXX. commercial gastrointestinal Patrick to Business disease and a forward I vidofludimus opportunities In with and systemically calcium addition small for SIRTX modulator potential partnership range Chief to that for Walsh, orally to our Immunic's disorders. my molecule readiness, work Officer, other look helping on both of working for acting targets

Roche, has As decades thought in and of month, we launches. of experience commercialization. efforts Daniel accumulating Simona successful of strategy It most health in [ worth noted, with Johnson a ] -- research portfolio double-digit which led global development for approvals Company, of MS. and States medicines internationally, and Eli & at business XX-year our and the in last with Board remains regulatory appointment the of out in growth drug the late and and corporate the including one treatment Skerjanec, or and Simona companies for Eculizumab, Pfizer Achieving Medicines neurological sustainable diseases. Over sales, with such that brain Roche's nearly strengthened led United in drug Lilly, numerous Working of Johnson. a career successful leader the commercial rare Directors is pointing development OCRed Simona as

over I Danny. will now the to call turn back

Daniel Vitt

Thank Yes. Jason. you,

development We in are very record really and MS proud with potential commercial strengthens launch MS. and Jason's combined of the towards work the calcium and as joined commercialization, Immunic excited and Simona's commercializing both you experience vidofludimus we launching team drug in in drugs Immunic that track Simona

and clinical all recent second quarter the making That We concludes with are our XXXX advancements summary remain programs. highlights. pleased the most and across we of operational

progressive regional we're our [ As lead both with relapsing to and II discussions trial pursue advancing companies. our global patients III the calcium, it Phase relates date, with Phase partnering pharmaceutical strong on there CALLIPER MS. XXX technical MS with ] insure trials to to evidence Based we were continue vidofludimus asset, in both and

Our in broad for of a the game orders. potential treatment become our the busy team changer to program, advancing has range [ a also of been IMU-XXX ] Didis has which

and exploring II indications. further in already, potentially of IMU-XXX, currently clinical our Phase calls to previous development mentioned options GI disease fund celiac are As we different in other

overview. turn Glenn? over to to I would the financial like now provide Glenn to call

Glenn Whaley

Thank will XX, review results months XXXX. now I the second X ended for Daniel. you, and June operating and quarter financial the

in me expect We our quarter XXXX. we of million the $XX.X third of our of quarter equivalents, into with cash a be 'XX able second the review with cash to and Let fund ended which start operations to position. cash

$XX.X driven were XX, June by the ended vidofludimus as increase XX, was development costs This IMU-XXX programs. $XX.X The development by ended Regarding expenses partially decrease million related XXXX. R&D months XXXX, the months the for clinical to operating for program. June for reductions the was compared million X external to results. offset and mainly in costs calcium the IMU-XXX in an X

R&D XX, offset XXXX. ended the in ended June ended and the period compared ended was consultant and increase compared $X.X XXXX, G&A programs, clinical mainly X $XX.X The million decrease legal IMU-XXX million primarily increase expenses IMU-XXX expenses. same was to expenses. development the June by and costs for related June X the June XXXX. for months XX, months for million by were XXXX, personnel the months For The to for million $X.X $XX as reductions were was to personnel an driven XX, XX, expenses partially as X which in

as XXXX, was compared X consultancy remained X period the XXXX. XXXX. XX, XXXX, to The to June Interest ended unchanged XX, as $X.X for compared to for June and the related income expenses were increase X For expenses. million $X.X ended million June million ended at months personnel, XX, G&A months ended XX, months primarily the the June same legal $X

For compared the interest ended The June XXXX. interest XX, same million period due as $X.X the rates. higher was to X $X.X June $XXX,XXX months to increase for XXXX, XX, income was ended million

reported of X and $X.X of change value X tranche also X of the in June the associated XX, January change change million to XXXX was value charge months for rights ended placement. We private with related The of the the in the a noncash the tranche the tranches XXXX. fair rights a future

incentives XXXX, increase income a Other partially as for result $X.X less offset foreign tax in an to XXXX. in which months by ended XX, exchange period decrease The the XX, spend attributable million million other ended gains, received and as in same clinical decrease June primarily in clinical for Australia $X.X the X R&D country. compared that a was was in grants of trials increase for to for a was June trials

was incentives million to ended financing the related primarily of XXXX million related XXXX, the in rights to expense well June tax Grant Ministry income in a clinical the closing as were a ended to costs a recognizing German of Finance R&D same $X.X For the to compared January June $X.X months decrease XX, The the the attributable the of of decrease that in million portion at of from XX, Australia. period trials negative XXXX. X the established as other for $X.X for was tranche Federal X timing time as tranche expense

in XXXX, shares common weighted the per a loss based $X.XX based diluted XX.X and or outstanding The As XXX.X average XXXX, million months million diluted decrease common that approximately was of million $X.XX $XX.X share for months ended XX, an and XX.X June average or per X for a was ended on or the same XX, shares basic $XX so million $X.XX weighted to $XX basic on the shares XXXX. based net per to the compared per Net and approximately gains. based diluted for compared on share loss $X.XX a average period XX, on million net common outstanding June approximately for average basic common result The share loss clinical partially weighted and offset outstanding diluted basic million in exchange for XXXX. million weighted trials of less million XX approximately share outstanding increase country. ended same approximately X period net foreign June of $XX.X XX, by spend loss approximately ended June shares or

will back upcoming to and milestones. Daniel? development pipeline over a Daniel I the review call that, of With turn for our

Daniel Vitt

data line reporting on CALLIPER of clinical would position you, development an of Thank anticipated patients. treatment programs FMS continues for neuroprotective for secondary from our need we our in effects to Yes. the unmet top as II the and approved Phase MS, provide highest anticipate to milestones. currently Glenn. year. vidofludimus I type April and the update therapeutics and next to available able calcium line If trial upcoming progress progressive progressive non-relapsing now eagerly may data We like medical top MS with option no first drug show be the oral the

[ this for Additionally, futility further XX treatment of in which We we size futility expect program quarter R&D the host next at on discuss XXXX. PMS III MS analysis second the City program expect inform insights in MS insurer fourth insured quarter approximately analysis will will trial September the identical of of relapsing half and nonbinding in provide to our profile second occurred of double-blind XX. adjustment. year groundbreaking unique and of the Phase patients. York XXXX Day, This in to calcium III of first allow our vidofludimus detailed a on the of report in both our potential for ] to have complete and the a and treatment plan to plan an analysis potential We New events choice become insure periods. half the the interim in trials development second its after We we our of to MS Phase RMS sample

Dr. range holistic Italy, top-notch Francesca who mass and I Motorola Pennsylvania, this MS is earlier who for in for of in today's Bar-Or we of the solution from Dr. University target leading calcium could from standard The protein of of will As also Hospital meaningfully experts providing one expert. patients. is noted vidofludimus [indiscernible] that the Torin neuroimmunologists the the call, improve Amit believe as well one by experience. full a care leading X industry of University event as well-known feature

forward having look our to much R&D such very speakers Day. excellent We at MS

biomarker It of that broad and from Phase of celiac of of disease gluten patients nutrient graft uniquely data that we second our this to gluten-free placebo stage celiac action remain targeting healing key in and the disease the of proof-of-concept host demonstrated intestinal patient response. relates treat we regeneration, bowel and asset, it repeating our protection of during catal mode dimensions about in such immunosuppression. results gas believe very versus epithelial absorption IMU-XXX, range improvement Ib periods of challenge is over clinical and As IMU-XXX disease, program [ disease. significant and improvements trial as diet disorders, believe physiological clinical enthusiastic broad clinical or of suited disease innovative absence with of enhancement ] IMU-XXX its architecture, treatment outcome in a inflammatory MX serious symptoms, gastrointestinal strong to bears senior By

and of gut Q&A contingent session. brings please clinical gastrointestinal begun exploring of of As we on partnering where to our a presentation. asset. in the previously have also we us is financing, disease, number other mall celiac renewal testing important, for end a further the or are the for open of This of call addition other licensing the IMU-XXX, II to applications formal Jessica, Phase clinical for preparing reported, the orders.

Jessica Breu

well Thank clinical quarter our Glenn pipeline. also highlights second and us as as and for development Yes. walking the subsequent Daniel, and Jason, you, through

now begin We question-and-answer will the session.

are a to if ways platform, the you As there the questions. webcast via X submit reminder, joined Zoom

tool raise can to writing you Zoom use function would Q&A via cure You the of the with questions please portal either in speak of hand if portal to us directly, submit like your question. or the the Zoom your

Our is Yasmeen Sandler.Yas and today first go from guest please ahead. Rahimi Piper unmute yourself

Yasmeen Rahimi

One -- if was need kind there will out studies, size you. update. in? that what for Is that of guess, questions much are is what -- studies, for all a you Thank A MS studies, be futility there standard could great insure when so the is, I you built that dissect about sample Phase adjustment. always your the for you questions current a the also design likelihood of III possible protocol talk and to the few

for And love would of tackle I in So CALLIPER. then a have to to follow-up regards I you that? sort

Daniel Vitt

Jasmine. the that it Thank the from very into very And -- you, was yes, beginning, clear, built was Yes. utility study.

yes of make an patients. couple a just we it's as sure not that wanted run random main is to predefine the One of or event-driven know, And limited the And study. we on for things. of adjustment you sample have options small We to no. size fertility short And analysis, just reasons number only the you therefore, a questions. committee with need can where say

very I program. and really overall that the studies important in really a of it invested, the straight think ensures III And Phase just thing. it's money So well and those makes succeed we

Yasmeen Rahimi

obviously, in then is brain CALLIPER, change. the at the to volume primary And endpoint looking regards Okay.

change -- that of XX% go what maybe we you the of be reminder should what Obviously, a about a you up of key see Like I'll for right? have secondaries differences, from you would 'XX of to et key ones hope EDSS as the in reflective be [ what consider pick think in I April, rate a are into guys walk back maybe to would scores, some love cetera. in analyzed do of but volume of measuring statistical nicely kind meaningful go and number differences. also are I we the able ] clinically test, secondaries, the you past, to talked sort sort

that queue. So kind of talk back about into I would love you then I'll well, for jump to as the

Daniel Vitt

is you that for for think major study the brain happy endpoint there Yes, the be active I'm -- which And the also patients but change. and MS are secondary I transformative primary are change. because said, volume could I the of the And meaningful. And the XX-milligram question placebo is a endpoints, and medically also very between I very mentioned company. asked really study EDSS think CALLIPER as you said, as dose. you

disability worsening. confirmed [ key the secondary worsening, XX So disability ]we so point official end confirm is secondary

We calcium part cognitive things And you have withstand we for test, report X-hole in there to could as also implemented we in what walk will also extent report us test which peg that, will other standard have and and has XX April. of that, on the those. help protective meant, functions, above new the we effects. And to the the study, are parameters vidofludimus

of those all And are meaningful.

designed study the to think full picture. really give was a I

excess I can tell patients have It's what of study others and see is randomized here. and right expectations the we of you threshold activity big now have study. overall XXX can What what high we We here. the a in is

in here step think. whatnot. every mentioned, for benefit what treatment, absence the for would medically there is success, a no something I but progressive, example, secondary as number official be disability think, forward relevant on non-relapsing you would any is But protection I and meaningful of As perceived be

Jessica Breu

here is Kaplan Matt one Thalmann. Ladenburg queue the Next from in

Matthew Kaplan

on Yasmeen's to CALLIPER. follow-up a Just question

terms why you give make the that the sense April? give confidence you NFL confident Just in of us or we'll that in changes you the a of see outcome observed interim study in study the in

Daniel Vitt

last which why a NFL good of the the newer work that maybe from of to of R&D the on if And author of that And paper relevance context of outcome. because with September. most of very Matt. author studies hints us Day, lot disability believed predicting most the predictive show they we population, good clearly other think the then a year. if at it he SSL spent relapses MS patients join rebaselining And in the rate Bar-Or, of I one shown don't coming you, MS. I of mean ocrelizumab or is of a and the the very did is those you have disability the really most low patients, NFL. literature study, and worsening Thank ] is was important that by will published in show lower than on study focus main for NFL inflammation, the level important question paper future understanding in a the [ for study really think was don't oratorial the rather Yes. be That's progressive role baseline lower the you for on Amit primary a at they disability

the last be for the XXX-week compared at reported NFL reduction caliber between full And for patients. optimistic makes shown very So back data we separating is of other I why and we really evaluation. it on us on There careful data relation have October that and very but this -- that was significant placebo, in studies they hands think a need tool, inventional interim a pretty significant. the very on next April inflammatory nice also studies, active -- statistical good statistically with we shown was disability is that where that data. it's nonimplementary NFL the set to point a really was the from readout which is on there this after are we therefore, that's correlation a protection non interventional that looking think big with think XX%

Jessica Breu

Partners. the Tom from Leerink is in one Next Smith please and unmute queue welcome. here Tom, yourself

Thomas Smith

I just Pharma Can potential engagement months other how elaborate level XX I last of business that's mean you to you explore vidofludimus. opportunities. one partnership in looking guess on over you now? partner? and the you're to with Just development and for a what mentioned evolved on the continue

Daniel Vitt

Maybe happy. to Yes, that over question. Jason, like would take you

Unknown Executive

Sure.

when we get can patients therefore, about help our only is patients continue successful, is ensure that medicine increase would right? partnerships, shareholders. look, but also the it think clearly, And as quickly value to not as to have to that if be we unmet for So company and as many goal to this need, for possible,

And so we're potential partnerships. of exploring variety a different

company. full-out regional share not big That licensing. to a is as the ourselves necessary begin these if launch others. and It just we and a partnerships. joined out-licensing. We limited commercial to if It could plans to believe Daniel that has at and a I've look be Again, mentioned, could go expertise as But reason profit drugs build will to responsibility partnerships in-house, we around building have we're well needed, ourselves. why it's forward

we this are both forward And different at the but time global not I partnerships, large for look mention will variety obviously to discussions also sharing specifics so information we regional companies. and in future. in of with a potential additional

Thomas Smith

are I Got then with feedback the what guess, celiac plans makes to starting And Phase receive one study? just on was engaged from the I where with you just a could little to XXX. if then more it. gating you factors And stand be the FDA? That wondering on sense. II the bit color or provide

Daniel Vitt

Yes.

of clinical data working to the the on edition now with options just looking a independent on are for do bet want to ensure programs. indication, speed we but programs. are more it's financing of have also we for right not broad so one And XXX think ongoing. on sites we we of and I the discussing company the And protocols, actively the really in do performance as of and we hopefully potential here. being way full to one in that X forth, said, exploring Therefore, than is I hopefully MS focus application preparation that able experts, the

very indication, of upward as smaller data, but mode indication, but it's have concept a is indication in a received interesting, after already disease. So there, perfectly disease action which where these the are also the graft-versus-host is proof provides of fits we good niche specifically, CDI

So of And have is we looking forward that we we at. context, have plan most kind in clear these some done and go to Phase in regulatory sure a design the steps potential discussions. investors things into work next right we to are think II the together are And and partners X big we studies. make the and right discussions the with have concept

Jessica Breu

you a use Once Q&A in hand here and welcome raise see again, Bussian go some the unmute and if please like I next would of queue. ahead. Brookline, the please function portal the tool, yourself to have the or more Zoom I question, Tyler from Tyler,

Tyler Bussian

data DHODH kind I secondary lot expedite a need -- sense get the come mechanisms caliber. something Track that? trial, of talking designed Daniel. amount And since results type compared some you those inhibition. A to to What, of readouts Obviously, I designation of what quick if through, the readouts any of a potential like kind that just wanted question you of a you on the effect would neuroprotective possibilities possibility? traditional to for of have large in neuroprotective from of data about and review for a see Fast kind there are guess, the is

Daniel Vitt

Thank you for question. the

Of course, the that depends data, on answer. that's the

You think you're offer with right. such questions. Well, always get I

progressive need. think the of also around study. [ the progressive This unmet I the And XXX ] area an also real for that the regulators secular MS. Given patients have aware nonrelapsing treatment XX% and is secondary of huge of in this I are considering non-relapsing of absence the world.

parameters maybe towards approval. protective the relevant effect able try expedite So and medically on for meaningful example, if showing also means volume brain with the will change disability to is good discuss to regulator on course, track what of extent are data We, and a good the other worsening to cognitive

very a happy in patients. a it's really positive something to get the -- could do. to think much drug really quicker be way to could be That it we'd case, the And I

Jessica Breu

yourself. B Azad one and please Riley. with Medicine next here is The from Medicine,

Unknown Analyst

Yes, I think it's fixed now.

Jessica Breu

better. Thank that's you. Yes,

Unknown Analyst

And -- expectations this class, filling think the starting floor with leapfrog class there's so Do of the your we've therapy kind you choice? of of in for I'm and already just come class? kind oral this kind me misses from couple given where of a if you efficacy this and maybe -- to you're BTK safety class. of wondering so seen the become seen the able for Thanks, drug I'm the then a the -- scenario of you've

Daniel Vitt

Yes.

of industry BTK we as there's disappointment RMS de a we data, that in lot ] I development, [ really -- think And the on PMS. a class still for to soon a inhibitors tried of expecting all was And patients. course, there, from the plate. think, to is I and for the option need that next need the and admit market evobrutinib for example, tolebrutinib develop the the I some think Sanofi to

that because they mode into pipeline. other potentially I the interesting think the action, lower fill data new development opened is could alternative evobrutinib which alternative more activator, good number is already, there a us to less or perception and my of for here is first-in-class with recognize really BTK of a in that doors an one molecule candidates

think, but still of there. out we I see we in will clinical So of some that has are and for inhibitors, the think what's yes, the it's clearly hold that already despite open, that BTK studies see impression, the we -- market U.S. the development, we coming they the in still

Unknown Analyst

-- II next population a wider is steps CALLIPER all it and secondly, a Or targeting are so early population? positive, of is to nonactive the of you that be to straight thinking Great. or go you'll of if would so, Okay. if or assuming Phase III PPE kind about too talk kind And PMS? Phase SPMS active then

Daniel Vitt

Yes.

So we're that. doing

think clinical team to about for We it. already duty. III our regardless Phase working or think the a Phase is if I We approval not protocol -- in this need the will expedited III is -- get needed. be on PMS we and

likely also, also side. on indication demand that likely progressive interim sense and of the least secondary And first in be and absence the III there quickest in will therefore, know the non-relapsing population, is other medically be treatments based drugs focus sufficient So we for and at on and the clearly, on biomarker makes Phase work given the MS. [indiscernible] should high this one any -- looking difficult-to-treat the focus that

that's the So think point that, our forward yes, view. way from I of

could be global in also a as strategy. global partnership. seen piece said, is this it a be However, of Jason the also

So other at the there ways doing look -- We're let's are the data. homework.

year. are We piece we I data table are options quarter strong is in And important the than get for the But to what of and to do have how they? prepared the different options. on next the second see most think

Jessica Breu

session any concludes This the would right. to like closing I Daniel today. to back for conference over turn remarks. our All question-and-answer

Daniel Vitt

calcium. call we Thank reiterating pipeline our you, our from today's Phase Jessica, next lead and program programs. thanks Phase data of our ENSURE I to line top enrollment how by the end vidofludimus and with to trials, all continue our tangible for expected II about insightful in of potential questions. excited always ongoing advanced III clinical attendees of make with trial like April to of progress we CALLIPER would the year your the are

Importantly, with company fund sheet quarter third on next of is million into the expected balance year. our to the which $XX.X

or of We unique CALLIPER its are and preparations months couple trial beyond potential is of licensing on the IMU-XXX capitalized of financing, broad progress our an serious gastrointestinal our contingent Initially, array clinical even Phase on to also expect update treatment ores. of the provide for for made and a as partnering, a we readout. II

not And to please I call. are out. we one, today's questions joining. would very to Thank that, for answer one With like additional happy by do hesitate reach close so to again you any

Jessica Breu

joining XXXX earnings quarter for call now concluded. The next has second you call. our Thank

disconnect. may now You

Immunic (IMUX) 8 Aug 242024 Q2 Earnings call transcript